Trial Profile
The impact of androgen deprivation therapy or androgen blockage therapy on the upregulation receptor activity of Gallium68 Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans in men with castrate resistant prostate cancer and the use of PSMA targeted therapies.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jul 2019
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- Acronyms ADT and Me Study
- 03 Aug 2017 New trial record